Author | Robert A. Huddart, MB, PhD, BS


Hypofractionated Regimen Safe, Feasible in Elderly Bladder Cancer Patients

November 08, 2017

In this interview we discuss results of the HYBRID trial, which tested a hypofractionated regimen of 36 Gy over six fractions in elderly muscle-invasive bladder cancer patients who were ineligible for standard treatments.